荟萃分析
多不饱和脂肪酸
心理干预
置信区间
优势比
精神病
安慰剂
医学
内科学
早期精神病
利培酮
随机对照试验
精神科
精神分裂症(面向对象编程)
心理学
脂肪酸
生物
替代医学
生物化学
病理
作者
Chengfeng Chen,Yongyan Deng,Yuling Li,Meiting Zhang,Tong Yu,Kun Xie,Wuyou Bao,Peiying Li,Sun Liu,Tianhong Zhang,Yikang Zhu,Bin Zhang
摘要
Abstract Background The efficacy of pharmacological and nutritional interventions in individuals at clinical high risk for psychosis (CHR-P) remains elusive. This study aims to investigate the efficacy of pharmacological and nutritional interventions in CHR-P and whether these interventions can enhance the efficacy of psychological treatments. Methods We systematically reviewed data from 5 databases until July 24, 2021: PubMed, Web of Science, EMBASE, China National Knowledge Infrastructure, and WanFang Data. The primary outcome was the transition to psychosis. Network meta-analyses were conducted at 3 time points (6, 12, and ≥24 months) considering both pharmacological/nutritional interventions alone and its combination with psychotherapy. Results Out of 11 417 identified references, 21 studies were included, comprising 1983 participants. CHR-P participants receiving omega-3 polyunsaturated fatty acids treatment were associated with a lower probability of transition compared with placebo/control at 6 months (odds ratio [OR] = 0.07, 95% confidence interval [CI] = .01 to .054), 12 months (OR = 0.14, 95% CI = .03 to .66), and ≥24 months (OR = 0.16, 95% CI = .05 to .54). Moreover, risperidone plus psychotherapy was associated with a lower likelihood of transition at 6 months compared with placebo/control plus psychotherapy, but this result was not sustained over longer durations. Conclusion Omega-3 polyunsaturated fatty acids helped in preventing transitions to psychosis compared with controls. PROSPERO registration number CRD42021256209.
科研通智能强力驱动
Strongly Powered by AbleSci AI